Title: Ustekinumab trough levels predicting laboratory and endoscopic remission in patients
with Crohn’s disease
Version: 1 Date: 07 Mar 2022
Reviewer:  Cher Shiong Chuah
Reviewer's report:
A good research article using hard endpoints (endoscopic remission) to evaluate ustekinumab
levels (which is of current and relevant interest given the limited data in the field).
Although the sample size n=28 may limit the conclusions, I think given the scarcity of this
data and the valuable nature of it, that it should be published. I would encourage the authors
to continue collecting more data on ustekinumab levels and endoscopic outcomes and perhaps
publish another manuscript in a few years (we know the difficulty of obtaining this data and that
it takes years to achieve) when the n number increases to a point where statistical significance
can be properly evaluated.
Title: Ustekinumab trough levels predicting laboratory and endoscopic remission in patients
with Crohn’s disease
Version: 1 Date: 07 Mar 2022
Reviewer:  Cher Shiong Chuah
Reviewer's report:
A good research article using hard endpoints (endoscopic remission) to evaluate ustekinumab
levels (which is of current and relevant interest given the limited data in the field).
Although the sample size n=28 may limit the conclusions, I think given the scarcity of this
data and the valuable nature of it, that it should be published. I would encourage the authors
to continue collecting more data on ustekinumab levels and endoscopic outcomes and perhaps
publish another manuscript in a few years (we know the difficulty of obtaining this data and that
it takes years to achieve) when the n number increases to a point where statistical significance
can be properly evaluated.
Please review this paper.
user
Title: Ustekinumab trough levels predicting laboratory and endoscopic remission in patients
with Crohn’s disease
Version: 1 Date: 07 Mar 2022
Reviewer:  Cher Shiong Chuah
Reviewer's report:
A good research article using hard endpoints (endoscopic remission) to evaluate ustekinumab
levels (which is of current and relevant interest given the limited data in the field).
Although the sample size n=28 may limit the conclusions, I think given the scarcity of this
data and the valuable nature of it, that it should be published. I would encourage the authors
to continue collecting more data on ustekinumab levels and endoscopic outcomes and perhaps
publish another manuscript in a few years (we know the difficulty of obtaining this data and that
it takes years to achieve) when the n number increases to a point where statistical significance
can be properly evaluated.
assistant